NextCure(NXTC) - 2022 Q4 - Annual Report

Financial Performance - The company reported significant losses and has never generated revenue from product sales, indicating a challenging financial position [18] - The company expects to continue incurring significant losses for the foreseeable future, highlighting the need for substantial additional financing [18] - The company has a history of significant losses and expects to continue incurring substantial losses for the foreseeable future, with no revenue generated from product sales to date [18] - The company requires substantial additional financing to pursue its business objectives, which may not be available on acceptable terms [18] Impact of COVID-19 - The impact of the COVID-19 pandemic continues to adversely affect the company's business operations and clinical trials [18] - The ongoing impact of the COVID-19 pandemic could adversely affect the company's business operations and clinical trials [18] Regulatory and Development Challenges - Regulatory approval processes for product candidates are lengthy and inherently unpredictable, which may delay commercialization [18] - The company is dependent on advancing its product candidates through preclinical studies and clinical trials, which involves uncertain outcomes [18] - The company has limited experience in designing and implementing clinical trials, which could result in delays or increased costs in product development [18] Intellectual Property Concerns - The company has filed patent applications for its product candidates but has obtained only a small number of patents, raising concerns about intellectual property protection [26] - The company has filed patent applications for its product candidates but has obtained only a small number of patents to date, which may affect its ability to commercialize products [26] Supply Chain and Competition Risks - The company relies on third-party suppliers for key materials in its manufacturing process, and any disruptions could harm its business [26] - The company relies on third-party suppliers for key materials in its manufacturing process, and any loss of these suppliers could harm its business [26] - The company faces significant competition from other biotechnology and pharmaceutical companies, which could impact its market position [26] - The company faces significant competition from other biotechnology and pharmaceutical companies, which could impact its operating results [26] Stock Volatility - The price of the company's common stock has been volatile and may fluctuate substantially, affecting investor confidence [26] - The price of the company's common stock has been volatile and may fluctuate substantially in the future [26] Human Resources Dependency - The company is highly dependent on key personnel, and failure to attract and retain qualified staff may hinder its business strategy [26] Collaboration Opportunities - The company may seek to establish additional collaborations for product development, and failure to do so on commercially reasonable terms may alter its plans [26]